Early detection of colorectal cancer (CRC) is essential for saving lives, yet 50 million eligible Americans are not up to date with screening. Current methods are often seen as inconvenient, leading to low adherence rates. A new non-invasive blood test, recommended by the FDA advisory committee, offers a simpler option with a higher completion rate. Approval of this test could significantly improve screening adherence and outcomes, especially as CRC incidence rises in younger populations.
Dr. Len Lichtenfeld emphasizes the importance of this advancement.
Keep Reading
Add A Comment